Table 2:
Correlation between Survivin expression and clinicopathological features of the
primary tumors.
|
Features |
Number
of cases (%) |
Survivin-expression in the primary tumors |
|
|||
|
Negative (0) |
Weak (+1) |
Moderate (+2) |
Strong (+3) |
P-value |
||
|
Age (years) |
|
|
|
|
|
0.650 |
|
< 49 years |
46(59%) |
13(28%) |
24(52%) |
8(18%) |
1(2%) |
|
|
≥ 49 years |
32(41%) |
12(37.5%) |
16(50%) |
4(12.5%) |
0(0%) |
|
|
Site of tumor |
|
|
|
|
|
0.021 |
|
Right |
43(55%) |
9(20.9%) |
25(58.1%) |
9(20.9%) |
0(0%) |
|
|
Left |
35(45%) |
16(45.7%) |
10(28.6%) |
9(25.7%) |
0(0%) |
|
|
Histological Type |
|
|
|
|
|
0.611 |
|
Invasive ductal carcinoma |
69(89%) |
21(30.4%) |
31(44.9%) |
0(0%) |
0(0%) |
|
|
Mucinous carcinoma |
3(4%) |
2(66.7%) |
1(33.3) |
0(0%) |
0(0%) |
|
|
Invasive lobular carcinoma |
3(4%) |
1(33.3%) |
2(66.7%) |
0(0%) |
0(0%) |
|
|
Papillary carcinoma |
1(1%) |
1(100%) |
0(0%) |
0(0%) |
0(0%) |
|
|
Secretory carcinoma |
1(1%) |
0(0%) |
1(100%) |
0(0%) |
0(0%) |
|
|
Cribriform carcinoma |
1(1%) |
0(0%) |
0(0%) |
1(100%) |
0(0%) |
|
|
Histological Grades |
|
|
|
|
|
0.431 |
|
G1 |
13(17%) |
7(53.8%) |
4(30.8%) |
2(15.4%) |
0(0%) |
|
|
G2 |
48(61%) |
12(25%) |
24(50%) |
12(25%) |
0(0%) |
|
|
G3 |
17(22%) |
6(35.3%) |
7(41.2%) |
4(23.5%) |
0(0%) |
|
|
Stage |
|
|
|
|
|
0.892 |
|
I |
6(8%) |
3(50%) |
1(16.7%) |
2(33.3%) |
0(0%) |
|
|
IIA |
23(29%) |
7(30.4%) |
10(43.5%) |
6(26.1%) |
0(0%) |
|
|
IIB |
13(17%) |
3(23.1%) |
7(53.8%) |
3(23.1%) |
0(0%) |
|
|
III |
1(1%) |
0(0%) |
1(100%) |
0(0%) |
0(0%) |
|
|
IIIA |
18(23%) |
5(27.8%) |
10(55.6%) |
3(16.7%) |
0(0%) |
|
|
IIIB |
1(1%) |
1(100%) |
0(0%) |
0(0%) |
0(0%) |
|
|
IV |
16(21%) |
6(37.5%) |
6(37.5%) |
4(25%) |
0(0%) |
|
|
Primary Tumor |
|
|
|
|
|
0.742 |
|
T1 |
6(8%) |
3(50%) |
1(16.7%) |
2(33.3%) |
|
|
|
T2 |
44(56%) |
12(27%) |
23(52.5%) |
9(20.5%) |
|
|
|
T3 |
28(36%) |
9(32%) |
11(39% |
8(33%) |
|
|
|
Lymph node involvement |
|
|
|
|
|
0.589 |
|
No |
35(45%) |
11(31.4%) |
14(40%) |
10(28.6%) |
0(0%) |
|
|
yes |
43(55%) |
14(32.6%) |
21(48.8%) |
8(18.6%) |
0(0%) |
|
|
Distance Metastases |
|
|
|
|
|
0.771 |
|
No |
62(79%) |
19(30.6%) |
29(46.8%) |
14(22.6%) |
0(0%) |
|
|
yes |
16(21%) |
6(37.5%) |
6(37.5%) |
4(25%) |
|
|
|
Chemotherapy |
|
|
|
|
|
0.200 |
|
No |
7(9%) |
4(57.1%) |
1(14.3%) |
2(28.6%) |
0(0%) |
|
|
Yes |
71(91%) |
21(29.6%) |
34(47.9%) |
16(22.5%) |
0(0%) |
|
|
Radiotherapy |
|
|
|
|
|
0.584 |
|
No |
26(33%) |
9(34.6%) |
13(50%) |
4(15.4%) |
0(0%) |
|
|
yes |
52(67%) |
16(30.8%) |
22(42.3%) |
14(26.9%) |
0(0%) |
|
|
Recurrence |
|
|
|
|
|
0.036 |
|
No |
70(90%) |
21(30%) |
34(48%) |
15(21.4%) |
0(0%) |
|
|
yes |
6(8%) |
3(50%) |
0(0%) |
3(50%) |
0(0%) |
|
|
Estrogen |
|
|
|
|
|
0.357 |
|
No |
32(41%) |
10(31.3%) |
12(37.5%) |
10(31.3%) |
0(0%) |
|
|
yes |
45(58%) |
14(31.1%) |
23(51.1%) |
8(17.8%) |
0(0%) |
|
|
Progesterone |
|
|
|
|
|
0.554 |
|
No |
31(40%) |
10(32.3%) |
12(38.7%) |
9(29%) |
0(0%) |
|
|
yes |
46(59%) |
14(30.4%) |
23(50%) |
9(19.6%) |
0(0%) |
|
|
Her-2 |
|
|
|
|
|
0.047 |
|
No |
59(76%) |
17(28.8%) |
31(52.5%) |
11(18.6%) |
0(0%) |
|
|
yes |
18(23%) |
7(38.9%) |
4(22.2%) |
7(38.9%) |
0(0%) |
|
|
Multifocality |
|
|
|
|
|
0.001 |
|
No |
70(90%) |
18(25.7%) |
34(48.6%) |
18(25.7%) |
0(0%) |
|
|
yes |
8(10%) |
7(87.5%) |
1(12.5%) |
0(0%) |
0(0%) |
|
|
Free surgical margin |
|
|
|
|
|
0.485 |
|
No |
16(21%) |
3(18.8%) |
9(56.3%) |
4(25%) |
0(0%) |
|
|
yes |
20(26) |
22(35.5%) |
26(41.9%) |
14(22.6%) |
0(0%) |
|
|
Vascular Invasion |
|
|
|
|
|
0.754 |
|
No |
58(74%) |
17(29.3%) |
27(46.6%) |
14(24.1%) |
0(0%) |
|
|
yes |
20(26%) |
8(40%) |
8(40%) |
4(20%) |
0(0%) |
|
|
Positive family history |
|
|
|
|
|
0.812 |
|
No |
74(95%) |
23(31.1%) |
34(45.9%) |
17(23%) |
0(0%) |
|
|
yes |
4(5%) |
2(50%) |
1(25%) |
1(25%) |
0(0%) |
|